|
1) Luznik L, Engstrom LW, Lannone R, et al. Posttransplantation cyclophosphamide facilitates engraftment of major histocompatibility complex-identical allogeneic marrow in mice conditioned with low-dose total body irradiation. Biol Blood Marrow Transplant. 2002; 8: 131-8
|
|
|
|
2) Luznik L, Jalla S, Engstrom LW, et al. Durable engraftment of major histocompatibility complex-incompatible cells after nonmyeloablative conditioning with fludarabine, low-dose total body irradiation, and posttransplantation cyclophosphamide. Blood. 2001; 98: 3456-64
|
|
|
|
|
|
3) Prigozhina TB, Elkin G, Khitrin S, et al. Prevention of acute graft-vs-host disease by a single low-dose cyclophosphamide injection following allogeneic bone marrow transplantation. Exp Hematol. 2008; 36: 1750-9
|
|
|
|
|
|
4) Luznik L and Fuchs EJ. High-dose, post-transplantation cyclophosphamide to promote graft-host tolerance after allogeneic hematopoietic stem cell transplantation. Immunol Res. 12 January 2010 DOI 10. 1007/s12026-009-8139-0 [Epub ahead of print]
|
|
|
|
|
|
5) Luznik L, OʼDonnell PV, Symons HJ, et al. HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, post-transplantation cyclophosphamide. Biol Blood Marrow Transplant. 2008; 14: 641-50
|
|
|
|
|
|
6) Luznik L, Bolaños-Meade J, Zahurak M, et al. High-dose cyclophosphamide as single-agent, short-course prophylaxis of graft-versus-host disease. Blood. 2010; 115: 3224-30
|
|
|
|
|
|
7) Kasamon YL, Luznik L, Leffell MS, et al. Nonmyeloablative HLA-haploidentical bone marrow transplantation with high-dose posttransplantation cyclophosphamide: effect of HLA disparity on outcome. Biol Blood Marrow Transplant. 2010; 16: 482-9
|
|
|
|
|
|
8) Finke J, Schmoor C, Lang H, et al. Matched and mismatched allogeneic stem-cell transplantation from unrelated donors using combined graft-versus-host disease prophylaxis including rabbit anti-T lymphocyte globulin. J Clin Oncol. 2003; 21: 506-13
|
|
|
|
|
|
9) Finke J, Bethge WA, Schmoor C, et al. Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial. Lancet Oncol. 2009; 10: 855-64
|
|
|
|
|
|
10) Kim HJ, Min WS, Cho BS, et al. Successful prevention of acute graft-versus-host disease using low-dose antithymocyte globulin after mismatched, unrelated, hematopoietic stem cell transplantation for acute myelogenous leukemia. Biol Blood Marrow Transplant. 2009; 15: 704-17
|
|
|
|
|
|
11) Kohrt HE, Turnbull BB, Lowsky R, et al. TLI and ATG conditioning with low risk of graft-versus-host disease retains antitumor reactions after allogeneic hematopoietic cell transplantation from related and unrelated donors. Blood. 2009; 114: 1099-109
|
|
|
|
|
|
12) Hamadani M, Blum W, Phillips G, et al. Improved nonrelapse mortality and infection rate with lower dose of antithymocyte globulin in patients undergoing reduced-intensity conditioning allogeneic transplantation for hematologic malignancies. Biol Blood Marrow Transplant. 2009; 15: 1422-30
|
|
|
|
|
|
13) Lu DP, Dong L, Wu T, et al. Conditioning including antithymocyte globulin followed by unmanipulated HLA-mismatched/haploidentical blood and marrow transplantation can achieve comparable outcomes with HLA-identical sibling transplantation. Blood. 2006; 107: 3065-73
|
|
|
|
|
|
14) Remberger M, Sundberg B. Low serum levels of total rabbit-IgG is associated with acute graft-versus-host disease after unrelated donor hematopoietic stem cell transplantation: results from a prospective study. Biol Blood Marrow Transplant. 2009; 15: 996-9
|
|
|
|
|
|
15) Bacigalupo A, Lamparelli T, Bosi A, et al. Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors: 2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO). Blood. 2001; 98: 2942-7
|
|
|
|
|
|
16) Remberger M, Svahn BM, Ringdén O, et al. Dose study of thymoglobulin during conditioning for unrelated donor allogeneic stem-cell trans-plantation. Transplantation. 2004; 78: 122-7
|
|
|
|
|
|
17) Call SK, Kasow KA, Hale GA, et al. Total and active rabbit antithymocyte globulin(rATG; Thymoglobulin)pharmacokinetics in pediatric patients undergoing unrelated donor bone marrow transplantation. Biol Blood Marrow Transplant. 2009; 15: 274-8
|
|
|
|
|